Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone

Area of Science:

• Psychiatry
• Pharmacology

Background:

• Schizophrenia treatment often involves antipsychotic medications.
• Patients previously treated with risperidone may require alternative or optimized therapies.
• Paliperidone extended-release (ER) is an active metabolite of risperidone, offering a different pharmacokinetic profile.

Purpose of the Study:

• To evaluate the efficacy of paliperidone ER in patients with acute schizophrenia symptoms who had prior exposure to risperidone.
• To compare the effects of paliperidone ER versus placebo in this specific patient population.

Main Methods:

• Post-hoc analysis of pooled data from three 6-week, double-blind, placebo-controlled trials.
• Inclusion criteria required prior risperidone treatment (> or =4 weeks within 2 weeks of study entry).
• Efficacy assessed using the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions-Severity (CGI-S), and Personal and Social Performance (PSP) scale.

Main Results:

• 198 patients met criteria (142 paliperidone ER, 56 placebo).
• Paliperidone ER showed statistically significant improvements (P<0.05) in PANSS, CGI-S, and PSP scores compared to placebo.
• Study completion rates were higher for paliperidone ER (61.3%) versus placebo (42.9%).
• Adverse events like headache and insomnia were comparable; agitation was slightly lower with paliperidone ER.

Conclusions:

• Paliperidone ER is a significantly more effective treatment than placebo for patients with acute symptoms who have previously been treated with risperidone.
• Paliperidone ER demonstrates efficacy in improving both symptom reduction and functional gains in this patient group.
• The findings support the use of paliperidone ER as a therapeutic option for patients transitioning from risperidone therapy.